AG
MREO

Artal Group’s Mereo BioPharma MREO Stock Holding History

Artal Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,500,000
Closed -$1.13M – 133
2022
Q4 		$1.13M Hold
1,500,000
– – 0.06% 103
2022
Q3 		$1.29M Hold
1,500,000
– – 0.06% 104
2022
Q2 		$1.68M Hold
1,500,000
– – 0.09% 104
2022
Q1 		$1.68M Hold
1,500,000
– – 0.07% 116
2021
Q4 		$2.4M Hold
1,500,000
– – 0.07% 127
2021
Q3 		$3.63M Hold
1,500,000
– – 0.08% 121
2021
Q2 		$4.75M Hold
1,500,000
– – 0.1% 122
2021
Q1 		$5.05M Buy
+1,500,000
New +$5.3M 0.09% 123

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group's MREO Position: Q1 2023 in Review

Artal Group sold out of Mereo BioPharma (MREO) in Q1 2023, closing a stake of 1,500,000 shares — an estimated $1.13M sold.

Artal Group first reported a position in MREO in Q1 2021 and held it in 8 quarters. The position peaked at $5.05M in Q1 2021. 58 funds tracked by Wall St. Rank hold MREO as of Q1 2023.

  • Artal Group reported no remaining Mereo BioPharma position as of Q1 2023 after selling out during the quarter.
  • Artal Group sold 1,500,000 Mereo BioPharma shares in Q1 2023, an estimated $1.13M.
  • Artal Group first reported a position in Mereo BioPharma in Q1 2021 and held it in 8 quarters.
  • Artal Group's Mereo BioPharma position peaked at $5.05M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.